SCHEDULE 13G/A: Poplar Point Capital Discloses 16.71% Stake in NovaBay Pharmaceuticals

Poplar Point Capital Management and its affiliates have disclosed a significant 16.71% beneficial ownership stake in NovaBay Pharmaceuticals, Inc., holding 971,654 shares of common stock.

Summary

• Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, Poplar Point Capital GP LLC, and Jad Fakhry (collectively, the "Reporting Persons") have jointly filed an Amendment No. 2 to Schedule 13G.
• The Reporting Persons collectively beneficially own 971,654 shares of NovaBay Pharmaceuticals, Inc. Common Stock.
• This ownership represents approximately 16.71% of the outstanding Common Stock, based on 5,816,204 shares outstanding as of March 25, 2025, as reported in NovaBay's Quarterly Report on Form 10-Q for the period ended September 30, 2024.
• Poplar Point Capital Partners LP directly owns the 971,654 shares.
• Poplar Point Capital Management LLC is the investment manager for Poplar Point Capital Partners LP.
• Poplar Point Capital GP LLC is the general partner of Poplar Point Capital Partners LP.
• Jad Fakhry is the manager of, and owns a controlling interest in, Poplar Point Capital Management LLC and Poplar Point Capital GP LLC.
• The shares are held with shared voting power and shared dispositive power among the Reporting Persons.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance data that would indicate a strong positive or negative sentiment.

Positives

• A significant ownership stake by an institutional investor like Poplar Point Capital Management may signal confidence in NovaBay Pharmaceuticals' long-term prospects.
• The filing indicates the shares were acquired and are held in the ordinary course of business, suggesting a passive investment rather than an immediate intent to influence control, which can provide stability.

Negatives

• The document is a standard ownership disclosure and does not contain information about NovaBay Pharmaceuticals' financial performance or operational challenges, thus no inherent negatives about the company itself are present.

Risks

• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11, which could still imply potential future engagement in corporate governance matters.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding NovaBay Pharmaceuticals' future performance or the Reporting Persons' future investment intentions beyond the stated purpose of holding shares in the ordinary course of business.

Industry Context

This filing reflects a significant ownership position by an investment firm in a pharmaceutical company, which is a common occurrence in the financial markets. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may be viewed positively, potentially signaling confidence in the company and attracting further investor interest.
• Company Management: Awareness of a large shareholder, even a passive one, can influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Investment Management